"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy" in Cell Reports.

The research group of Prof. Lukas Sommer together with researchers from the University Hospital Zurich recently published their findings in Cell Reports:

In tumor immunotherapy, the body’s own defense system is activated against the tumor cells. However, the tumor cells frequently become resistant to the treatments used and the underlying mechanisms have been largely unknown. By using animal models, the study shows that an epigenetic control protein is key to the development of this resistance in skin cutaneous melanoma.

Further information can be found here:

UZH News release, 25 July 2017

Robert Andreas Wäger

News